TON - August 2013 Vol 6 No 7
Vanderbilt University School of Nursing is affiliated with Vanderbilt University School of Medicine and the Ingram Cancer Center, one of the National Cancer Institute (NCI)–designated Centers of Excellence.
The Importance of the Nurse- Patient Interaction in Optimizing Treatment With Ipilimumab for Advanced Melanoma
The announcement this spring by Angelina Jolie that she had undergone a risk-reducing double mastectomy after learning she carried a mutation in the BRCA1 gene, as well as the recent US Supreme Court decision on gene patenting, has resulted in an influx of questions to both genetic providers and support organizations about hereditary breast cancer.
In last month’s issue of The Oncology Nurse-APN/PA (TON), we published a letter from Cindy Covington. Cindy, an infusion nurse from Georgia, was responding to MMA’s “The Devil Is in the Details” column (see the TON April issue). MMA discussed how some of her needs as a hospitalized patient were not met and she thought her nurses should be able to help.
At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, several sessions focused on recent advances in melanoma, including new ways to boost the activity of current therapies, the development of a new class of immunotherapy, and a new form of immunotherapy—an oncolytic vaccine.
Sorafenib has become the first drug in years to prove effective in the treatment of differentiated thyroid cancer (DTC) that has become resistant to radioactive iodine (RAI), according to phase 3 study results reported at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.
Results 1 - 8 of 8